Fasciitis, Plantar
Conditions
Keywords
Chronic plantar fasciitis, Heel pain
Brief summary
Prospective, double-blinded, randomized controlled trial of the micronized dHACM injection as compared to the saline placebo injection in the treatment of plantar fasciitis
Detailed description
Approximately 276 patients will be enrolled in this study. Each patient will receive 1 injection and be evaluated for efficacy and safety during a 6-month observation period. Randomization will be 1:1. The study is expected to be completed within 34 months, inclusive of enrollment and follow-up of all subjects.
Interventions
OTHERMicronized dHACM
1 mL injection of 40 mg Micronized dehydrated human amnion/chorion membrane (dHACM)
DRUGSaline Injection
Injection of 1mL 0.9% Sodium Chloride Injection, USP
Sponsors
MiMedx Group, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
21 Years to 79 Years
Healthy volunteers
No
Inclusion criteria
1. Confirmed diagnosis of plantar fasciitis for ≥ 1 month (30 days) and ≤ 18 months by the investigator 2. VAS Pain scale of ≥ 45 mm at randomization 3. Plantar fasciitis with conservative treatment for ≥ 1 month (30 days), including any of the following modalities: * RICE * Stretching exercises * NSAIDs * Orthotics 4. Diagnostic X-Ray within 6 months of enrollment showing view of calcaneus negative for calcaneal fracture or structural abnormalities 5. BMI ≤ 40 kg/m2 6. Age ≥ 21 years and \< 80 years 7. Ability to sign Informed Consent and Release of Medical Information Forms 8. Ability to receive and respond to text messages or emails on a daily basis.
Exclusion criteria
1. Prior surgery or trauma to the affected site 2. Subjects requiring bilateral plantar fasciitis treatment at time of enrollment 3. Prior use of any lower limb injection therapy, including corticosteroids or PRP in either limb within the last 3 months 4. Has diabetes either Type I or Type II. 5. Systemic disorders associated with enthesopathy (disorder of entheses, i.e. bone attachments) such as Gout, Reiter's syndrome, rheumatoid arthritis, etc. 6. The presence of diagnosed comorbidities that can be confused with or can exacerbate the condition- to be assessed by X-ray - including but not limited to: * Calcaneal stress fracture * Nerve entrapment syndrome (diagnosed as Baxter Nerve Syndrome) * Fat pad atrophy * Acute traumatic rupture of the plantar fascia * Calcaneal tumor * Tarsal tunnel syndrome (diagnosed) * Significant bone deformity of the foot that may interfere with the study 7. Affected site exhibits clinical signs and symptoms of infection 8. Known allergy or known sensitivity to Aminoglycosides 9. Subjects who are non-ambulatory 10. History of more than 14 days treatment with immuno-suppressants (including systemic corticosteroids) or cytotoxic chemotherapy within 30 days prior to enrollment, or who are anticipated to require such medications during the course of the study 11. Prior radiation at the site 12. Use of any investigational drug(s) or therapeutic device(s) within 3 months preceding enrollment 13. Immune disorders including Systemic Lupus Erythematosus (SLE), Fibromyalgia, Acquired Immunodeficiency Syndrome (AIDS) or Human Immunodeficiency Virus (HIV) 14. History of any condition (including drug or alcohol abuse, medical or psychiatric condition) that is likely to impair understanding of or compliance with the study protocol, in the judgment of the investigator 15. Pregnancy at enrollment or within last 6 months, women who are breastfeeding, or women of childbearing potential who are planning to become pregnant during the time of the study OR are unwilling/unable to use acceptable methods of contraception (birth control pills, barriers, or abstinence) 16. Workers' compensation subjects
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in VAS score | 90 Days | Visual Analog Scale for Pain: |
| Incidence of adverse events | 180 Days | The incidence of related Adverse Events (AEs), Serious Adverse Events (SAEs), and Unanticipated Adverse Events during the first 12 months post injection |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Foot Function Index - Revised (FFI-R) (Short Form) | 90 Days | Foot Function Index - Revised: Patient Reported Questionnaire |
Countries
United States
Outcome results
None listed